melatonin has been researched along with Neurodegenerative Diseases in 98 studies
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One of the host risk factors involved in aging-related diseases is coupled with the reduction of endogenous melatonin (MLT) synthesis in the pineal gland." | 9.12 | Melatonin as a promising modulator of aging related neurodegenerative disorders: Role of microRNAs. ( Alamdari, AF; Kashani, HRK; Rahnemayan, S; Rajabi, H; Rezabakhsh, A; Sanaie, S; Vahed, N, 2021) |
| "Melatonin is known to possess several properties of value for healthy aging, as a direct and indirect antioxidant, protectant and modulator of mitochondrial function, antiexcitotoxic agent, enhancer of circadian amplitudes, immune modulator and neuroprotectant." | 8.91 | Melatonin and brain inflammaging. ( Brown, GM; Cardinali, DP; Hardeland, R; Pandi-Perumal, SR, 2015) |
| "Melatonin plays a neuroprotective role in models of neurodegenerative diseases." | 8.85 | The antiapoptotic activity of melatonin in neurodegenerative diseases. ( Wang, X, 2009) |
| "This study aimed to investigate the potential protective effects of melatonin (Mel) against aluminium-induced neurodegenerative changes in aging Wistar rats (24-28months old)." | 7.80 | Effects of melatonin on aluminium-induced neurobehavioral and neurochemical changes in aging rats. ( Allagui, MS; Badraoui, R; Bouoni, Z; Elfeki, A; Feriani, A; Murat, JC; Nciri, R; Saoudi, M, 2014) |
| "Melatonin secretion is an endogenous synchronizer, and it may possess some anti-aging properties." | 7.72 | Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. ( Cinchetti, W; Cravello, L; Ferrari, E; Fioravanti, M; Guazzoni, V; Magri, F; Sarra, S, 2004) |
| "In most countries, neurodegenerative diseases are generally recognized as the number one cause afflicting the elderly." | 7.01 | Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress. ( Joo, SS; Yoo, YM, 2023) |
| "Brain disorders such as Alzheimer's and Parkinson's disease (PD) are irreversible conditions with several cognitive problems, including learning disabilities, memory loss, movement abnormalities, and speech problems." | 6.72 | Melatonin hormone as a therapeutic weapon against neurodegenerative diseases. ( Alghamdi, S; Almehmadi, M; Asefy, Z; Dablool, AS; Eftekhari, A; Hoseinnejhad, S; Kazemi, E; Khusro, A; Mammadova, S; Sahibzada, MUK, 2021) |
| "Melatonin is an ancient molecule that is evident in high concentrations in various tissues throughout the body." | 6.72 | Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders. ( Brown, GM; Gonçalves, VF; Kennedy, JL; Melhuish Beaupre, LM, 2021) |
| "The prevention of neurodegenerative disorders has become an emerging public health challenge for our society." | 6.66 | Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020) |
| "Melatonin is an endogenous hormone produced by the pineal gland as well as many other tissues and organs." | 6.58 | Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases. ( Arribas, RL; de Los Ríos, C; Egea, J; Romero, A, 2018) |
| "Melatonin is an endogenous compound with a variety of physiological roles." | 6.55 | Melatonin as a mitochondrial protector in neurodegenerative diseases. ( Govitrapong, P; Wongprayoon, P, 2017) |
| "Treatment with melatonin effectively improved the clinical and neurophysiological aspects of rapid eye movement (REM) sleep behavior disorder (RBD), especially elderly individuals with underlying neurodegenerative disorders." | 6.53 | Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. ( Chen, XY; Ding, T; Jia, QZ; Su, SW; Zhang, T; Zhang, W; Zhu, ZN, 2016) |
| "Effective treatments for the sleep disorders associated with neurodegenerative diseases are urgently needed, but current data are insufficient to establish melatonin as such a treatment." | 6.53 | Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases. ( Karroum, EG; Trotti, LM, 2016) |
| "Treatment with melatonin is useful in a diverse range of medical conditions, including bipolar disorder, Alzheimer's disease, depression and fibromyalgia." | 6.50 | Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. ( Anderson, G; Maes, M, 2014) |
| "Melatonin has potential utility both in slowing normal brain aging and in treatment of neurodegenerative conditions." | 6.44 | Melatonin and the aging brain. ( Bondy, SC; Sharman, EH, 2007) |
| "Melatonin plays a role in the biologic regulation of circadian rhythms, sleep, mood, reproduction, tumor growth and aging." | 6.43 | The role of melatonin in the neurodegenerative diseases. ( Kotulska, K; Lewin-Kowalik, J; Marcol, W; Olakowska, E, 2005) |
| "Melatonin has been shown to be effective in arresting neurodegenerative phenomena seen in experimental models of Alzheimer's disease, Parkinsonism and ischemic stroke." | 6.43 | Role of melatonin in neurodegenerative diseases. ( Cardinali, DP; Esquifino, AI; Hardeland, R; Maestroni, GJ; Pandi-Perumal, SR; Srinivasan, V, 2005) |
| "Melatonin has attained increasing prominence as a candidate for ameliorating these changes occurring during senescence." | 6.42 | Retardation of brain aging by chronic treatment with melatonin. ( Bondy, SC; Campbell, A; Lahiri, DK; Perreau, VM; Sharman, EH; Sharman, KZ; Zhou, J, 2004) |
| "Melatonin is a hormone secreted by the pineal gland, mostly in the dark period of the light/dark cycle, with corresponding fluctuations reflected in the plasma melatonin levels." | 6.42 | Melatonin, metals, and gene expression: implications in aging and neurodegenerative disorders. ( Bondy, S; Chen, D; Greig, NH; Lahiri, DK; Lahiri, P; Rogers, JT, 2004) |
| "Pretreatment with melatonin significantly reversed METH-induced APP-cleaving secretases and Aβ production." | 5.72 | Melatonin Attenuates Methamphetamine-Induced Alteration of Amyloid β Precursor Protein Cleaving Enzyme Expressions via Melatonin Receptor in Human Neuroblastoma Cells. ( Boontor, A; Govitrapong, P; Nopparat, C; Panmanee, J, 2022) |
| "One of the host risk factors involved in aging-related diseases is coupled with the reduction of endogenous melatonin (MLT) synthesis in the pineal gland." | 5.12 | Melatonin as a promising modulator of aging related neurodegenerative disorders: Role of microRNAs. ( Alamdari, AF; Kashani, HRK; Rahnemayan, S; Rajabi, H; Rezabakhsh, A; Sanaie, S; Vahed, N, 2021) |
| "Melatonin is known to possess several properties of value for healthy aging, as a direct and indirect antioxidant, protectant and modulator of mitochondrial function, antiexcitotoxic agent, enhancer of circadian amplitudes, immune modulator and neuroprotectant." | 4.91 | Melatonin and brain inflammaging. ( Brown, GM; Cardinali, DP; Hardeland, R; Pandi-Perumal, SR, 2015) |
| "Melatonin plays a neuroprotective role in models of neurodegenerative diseases." | 4.85 | The antiapoptotic activity of melatonin in neurodegenerative diseases. ( Wang, X, 2009) |
| "This brief review considers the potential role of melatonin in the processes of aging, the prolongation of life span and health in the aged." | 4.81 | Melatonin, longevity and health in the aged: an assessment. ( Lopez-Burillo, S; Mayo, JC; Reiter, RJ; Sainz, RM; Tan, DX, 2002) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "This observation suggests that targeting of Notch1 signaling might be a promising therapeutic approach for AD and other age-associated neurodegenerative diseases, and melatonin might serve as a potential therapeutic agent for AD and other age-associated neurodegenerative diseases." | 4.31 | Regulatory role of melatonin in Notch1 signaling pathway in cerebral cortex of Aβ ( Bi, J; Hu, C; Ren, L; Wang, P; Zhang, S, 2023) |
| "This study aimed to investigate the potential protective effects of melatonin (Mel) against aluminium-induced neurodegenerative changes in aging Wistar rats (24-28months old)." | 3.80 | Effects of melatonin on aluminium-induced neurobehavioral and neurochemical changes in aging rats. ( Allagui, MS; Badraoui, R; Bouoni, Z; Elfeki, A; Feriani, A; Murat, JC; Nciri, R; Saoudi, M, 2014) |
| "We demonstrate that methazolamide and melatonin are neuroprotective against cerebral ischemia and provide evidence of the effectiveness of a mitochondrial-based drug screen in identifying neuroprotective drugs." | 3.75 | Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. ( Day, AL; Figueroa, BE; Friedlander, RM; Kristal, BS; Sirianni, AC; Stavrovskaya, IG; Wang, X; Zhang, Y; Zhu, S, 2009) |
| "Melatonin secretion is an endogenous synchronizer, and it may possess some anti-aging properties." | 3.72 | Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians. ( Cinchetti, W; Cravello, L; Ferrari, E; Fioravanti, M; Guazzoni, V; Magri, F; Sarra, S, 2004) |
| "Melatonin levels decrease with aging in mice." | 3.72 | Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex. ( Bondy, SC; Chen, D; Ge, YW; Lahiri, DK; Sharman, EH, 2004) |
| "Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common neurodegenerative diseases worldwide." | 3.01 | Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association. ( Esmaeili, A; Ghasemnejad-Berenji, M; Khezri, MR, 2023) |
| "In most countries, neurodegenerative diseases are generally recognized as the number one cause afflicting the elderly." | 3.01 | Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress. ( Joo, SS; Yoo, YM, 2023) |
| "Brain disorders such as Alzheimer's and Parkinson's disease (PD) are irreversible conditions with several cognitive problems, including learning disabilities, memory loss, movement abnormalities, and speech problems." | 2.72 | Melatonin hormone as a therapeutic weapon against neurodegenerative diseases. ( Alghamdi, S; Almehmadi, M; Asefy, Z; Dablool, AS; Eftekhari, A; Hoseinnejhad, S; Kazemi, E; Khusro, A; Mammadova, S; Sahibzada, MUK, 2021) |
| "Melatonin is an ancient molecule that is evident in high concentrations in various tissues throughout the body." | 2.72 | Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders. ( Brown, GM; Gonçalves, VF; Kennedy, JL; Melhuish Beaupre, LM, 2021) |
| "The prevention of neurodegenerative disorders has become an emerging public health challenge for our society." | 2.66 | Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases. ( Chen, D; Lee, TH; Zhang, T, 2020) |
| "Melatonin is a multifunctional signalling molecule that is secreted by the mammalian pineal gland, and also found in a number of organisms including plants and bacteria." | 2.66 | Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders. ( Nathaniel, TI; Olowe, OA; Onaolapo, AY; Onaolapo, OJ; Udoh, DO; Udoh, MO, 2020) |
| "Melatonin has been reported to have multiple roles in the central nervous system (CNS), including improving neurogenesis and synaptic plasticity, suppressing neuroinflammation, enhancing memory function, and protecting against oxidative stress." | 2.61 | Pineal gland dysfunction in Alzheimer's disease: relationship with the immune-pineal axis, sleep disturbance, and neurogenesis. ( Song, J, 2019) |
| "Neurodegenerative diseases are typified by neuronal loss associated with progressive dysfunction and clinical presentation." | 2.61 | The role of melatonin in targeting cell signaling pathways in neurodegeneration. ( Chinchalongporn, V; Govitrapong, P; Reiter, RJ; Shukla, M, 2019) |
| "In Alzheimer's disease and Parkinson's disease, WNT/beta-catenin pathway is downregulated while PPAR gamma is upregulated." | 2.58 | Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms. ( Guillevin, R; Lecarpentier, Y; Vallée, A; Vallée, JN, 2018) |
| "Melatonin is an endogenous hormone produced by the pineal gland as well as many other tissues and organs." | 2.58 | Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases. ( Arribas, RL; de Los Ríos, C; Egea, J; Romero, A, 2018) |
| "Melatonin is an endogenous compound with a variety of physiological roles." | 2.55 | Melatonin as a mitochondrial protector in neurodegenerative diseases. ( Govitrapong, P; Wongprayoon, P, 2017) |
| "Melatonin is an indoleamine produced mainly in the pineal gland." | 2.55 | Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration. ( de Los Ríos, C; Egea, J; Marco-Contelles, J; Ramos, E; Romero, A, 2017) |
| "Treatment with melatonin effectively improved the clinical and neurophysiological aspects of rapid eye movement (REM) sleep behavior disorder (RBD), especially elderly individuals with underlying neurodegenerative disorders." | 2.53 | Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. ( Chen, XY; Ding, T; Jia, QZ; Su, SW; Zhang, T; Zhang, W; Zhu, ZN, 2016) |
| "Effective treatments for the sleep disorders associated with neurodegenerative diseases are urgently needed, but current data are insufficient to establish melatonin as such a treatment." | 2.53 | Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases. ( Karroum, EG; Trotti, LM, 2016) |
| "Sleep disorders and neurodegenerative diseases are commonly encountered in primary care." | 2.53 | Importance of Rapid Eye Movement Sleep Behavior Disorder to the Primary Care Physician. ( Howell, MJ; McCarter, SJ, 2016) |
| "Melatonin was reported to prevent mitochondrial dysfunction from oxidative damage by preserving cardiolipin integrity, and this may explain, at least in part, the beneficial effect of this compound in mitochondrial physiopathology." | 2.52 | Protective role of melatonin in mitochondrial dysfunction and related disorders. ( Paradies, G; Paradies, V; Petrosillo, G; Ruggiero, FM, 2015) |
| "Melatonin has unique biochemical properties such as scavenging of hydroxyl, carbonate, alkoxyl, peroxyl and aryl cation radicals and stimulation of activities main antioxidative enzymes (glutathione peroxidase, superoxide dismutase etc." | 2.52 | Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders. ( Miller, E; Morel, A; Saluk, J; Saso, L, 2015) |
| "Melatonin treatment showed a potent neuroprotective action in experimental models and in clinical studies." | 2.52 | Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology. ( Biswas, J; Joshi, N; Nath, C; Singh, S, 2015) |
| "Treatment with melatonin is useful in a diverse range of medical conditions, including bipolar disorder, Alzheimer's disease, depression and fibromyalgia." | 2.50 | Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. ( Anderson, G; Maes, M, 2014) |
| "Neurodegenerative diseases are chronic and progressive disorders characterized by selective destruction of neurons in motor, sensory and cognitive systems." | 2.50 | Role of melatonin supplementation in neurodegenerative disorders. ( Bevelacqua, V; Cuzzocrea, S; Esposito, E; Guarneri, C; Polimeni, G, 2014) |
| "Melatonin is an indolamine with a large spectrum of functions that can be divided into chronobiotic and nonchronobiotic." | 2.47 | Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders. ( Cecon, E; Markus, RP, 2011) |
| "The treatment of neurodegenerative diseases is a major challenge in medicine." | 2.46 | An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders. ( Beas-Zarate, C; Camins, A; Folch, J; Junyent, F; Pallas, M; Sureda, FX; Verdaguer, E, 2010) |
| "Melatonin is an ancient molecule present in unicellular organisms at the very early moment of life." | 2.44 | Melatonin role in the mitochondrial function. ( Acuna-Castroviejo, D; Escames, G; Lopez, LC; Rodriguez, MI, 2007) |
| "Melatonin has potential utility both in slowing normal brain aging and in treatment of neurodegenerative conditions." | 2.44 | Melatonin and the aging brain. ( Bondy, SC; Sharman, EH, 2007) |
| "Edaravone has been shown to reduce oxidative stress, edema, infarct volume, inflammation and apoptosis following ischemic injury of the brain in the adult as well as decrease free radical production in the neonatal brain following hypoxic-ischemic insult." | 2.44 | Antioxidants and neuroprotection in the adult and developing central nervous system. ( Kaur, C; Ling, EA, 2008) |
| "Melatonin plays a role in maintaining sleep-wake rhythms; supplementation may help to regulate sleep disturbance that occur with jet lag, rotating shift-work and depression." | 2.44 | Neurobiological effects of melatonin as related to cancer. ( Hoang, BX; Levine, SA; Pham, PT; Shaw, DG, 2007) |
| "Melatonin plays a role in the biologic regulation of circadian rhythms, sleep, mood, reproduction, tumor growth and aging." | 2.43 | The role of melatonin in the neurodegenerative diseases. ( Kotulska, K; Lewin-Kowalik, J; Marcol, W; Olakowska, E, 2005) |
| "Melatonin has been shown to be effective in arresting neurodegenerative phenomena seen in experimental models of Alzheimer's disease, Parkinsonism and ischemic stroke." | 2.43 | Role of melatonin in neurodegenerative diseases. ( Cardinali, DP; Esquifino, AI; Hardeland, R; Maestroni, GJ; Pandi-Perumal, SR; Srinivasan, V, 2005) |
| "Melatonin has attained increasing prominence as a candidate for ameliorating these changes occurring during senescence." | 2.42 | Retardation of brain aging by chronic treatment with melatonin. ( Bondy, SC; Campbell, A; Lahiri, DK; Perreau, VM; Sharman, EH; Sharman, KZ; Zhou, J, 2004) |
| "Melatonin is a hormone secreted by the pineal gland, mostly in the dark period of the light/dark cycle, with corresponding fluctuations reflected in the plasma melatonin levels." | 2.42 | Melatonin, metals, and gene expression: implications in aging and neurodegenerative disorders. ( Bondy, S; Chen, D; Greig, NH; Lahiri, DK; Lahiri, P; Rogers, JT, 2004) |
| "Melatonin was recently reported to be an effective free radical scavenger and antioxidant." | 2.40 | Oxidative damage in the central nervous system: protection by melatonin. ( Reiter, RJ, 1998) |
| "Treatment with melatonin and dopaminergic neuron transplantation increased the number of neurons in substantia nigra and striatum while the number of glial cell and the volume of substantia nigra and striatum did not show significant change between groups." | 1.72 | The effect of dopaminergic neuron transplantation and melatonin co-administration on oxidative stress-induced cell death in Parkinson's disease. ( Abbaszadeh, HA; Abdollahifar, MA; Aliaghaei, A; Asemi-Rad, A; Ebrahimi, MJ; Heidari, MH; Moafi, M; Sadeghi, Y, 2022) |
| "Pretreatment with melatonin significantly reversed METH-induced APP-cleaving secretases and Aβ production." | 1.72 | Melatonin Attenuates Methamphetamine-Induced Alteration of Amyloid β Precursor Protein Cleaving Enzyme Expressions via Melatonin Receptor in Human Neuroblastoma Cells. ( Boontor, A; Govitrapong, P; Nopparat, C; Panmanee, J, 2022) |
| "NAFLD was induced by HFHF diet for 8 consecutive weeks." | 1.56 | Melatonin regulates neurodegenerative complications associated with NAFLD via enhanced neurotransmission and cellular integrity: a correlational study. ( A Abdel Jaleel, G; A Al-Awdan, S; A H Ahmed-Farid, O; F Ahmed, R; Saleh, DO, 2020) |
| "Melatonin is an endogenous pleiotropic molecule which orchestrates regulatory functions and protective capacity against age-related ailments." | 1.48 | Melatonin induces mechanisms of brain resilience against neurodegeneration. ( Cardoso, BR; Corpas, R; Franciscato Cozzolino, SM; García de Frutos, P; Griñán-Ferré, C; Pallàs, M; Palomera-Ávalos, V; Porquet, D; Rodríguez-Farré, E; Sanfeliu, C, 2018) |
| " To enhance the bioavailability of melatonin, we applied liposomal melatonin." | 1.42 | Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCδ gene. ( Cho, HJ; Dang, DK; Hong, JS; Jang, CG; Jeong, JH; Kim, HC; Lee, J; Lee, JC; Nabeshima, T; Nam, Y; Nguyen, TT; Nguyen, XK; Park, DH; Shin, EJ, 2015) |
| "Melatonin is a multifunctional molecule and plays a crucial role in the regulation of circadian rhythms." | 1.42 | Melatonin Attenuates Memory Impairment, Amyloid-β Accumulation, and Neurodegeneration in a Rat Model of Sporadic Alzheimer's Disease. ( Kiseleva, E; Kolosova, NG; Maksimova, KY; Muraleva, NA; Rudnitskaya, EA; Stefanova, NA, 2015) |
| "Astrogliosis was evidenced by increased GFAP immunoreactivity in the areas of severe neuronal degeneration at 5 days after DA administration." | 1.32 | Protective role of melatonin in domoic acid-induced neuronal damage in the hippocampus of adult rats. ( Ananth, C; Gopalakrishnakone, P; Kaur, C, 2003) |
| "Melatonin was as effective as GSH and was less effective than Trolox (a water-soluble analogue of vitamin E) in inhibiting iron-elevated lipid peroxidation of brain homogenates." | 1.31 | Melatonin suppresses iron-induced neurodegeneration in rat brain. ( Ho, LT; Lin, AM, 2000) |
| "Melatonin has been investigated as a possible copper ion chelator." | 1.31 | The effect of copper on (3H)-tryptophan metabolism in organ cultures of rat pineal glands. ( Daya, S; Parmar, P, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.04) | 18.2507 |
| 2000's | 25 (25.51) | 29.6817 |
| 2010's | 43 (43.88) | 24.3611 |
| 2020's | 28 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lajarín-Cuesta, R | 1 |
| Nanclares, C | 1 |
| Arranz-Tagarro, JA | 1 |
| González-Lafuente, L | 2 |
| Arribas, RL | 2 |
| Araujo de Brito, M | 1 |
| Gandía, L | 1 |
| de Los Ríos, C | 3 |
| Fan, X | 1 |
| Li, J | 1 |
| Deng, X | 1 |
| Lu, Y | 1 |
| Feng, Y | 1 |
| Ma, S | 1 |
| Wen, H | 1 |
| Zhao, Q | 1 |
| Tan, W | 1 |
| Shi, T | 1 |
| Wang, Z | 1 |
| Galano, A | 1 |
| Guzmán-López, EG | 1 |
| Reiter, RJ | 8 |
| Asefy, Z | 1 |
| Khusro, A | 1 |
| Mammadova, S | 1 |
| Hoseinnejhad, S | 1 |
| Eftekhari, A | 1 |
| Alghamdi, S | 1 |
| Dablool, AS | 1 |
| Almehmadi, M | 1 |
| Kazemi, E | 1 |
| Sahibzada, MUK | 1 |
| Ravikumar, M | 1 |
| Mohan, S | 1 |
| Velpandian, C | 1 |
| Shen, X | 1 |
| Tang, C | 1 |
| Wei, C | 1 |
| Zhu, Y | 1 |
| Xu, R | 1 |
| Nopparat, C | 1 |
| Boontor, A | 1 |
| Panmanee, J | 1 |
| Govitrapong, P | 3 |
| Majidazar, R | 1 |
| Rezazadeh-Gavgani, E | 1 |
| Sadigh-Eteghad, S | 1 |
| Naseri, A | 1 |
| Li, LB | 1 |
| Fan, YG | 1 |
| Wu, WX | 1 |
| Bai, CY | 1 |
| Jia, MY | 1 |
| Hu, JP | 1 |
| Gao, HL | 1 |
| Wang, T | 1 |
| Zhong, ML | 1 |
| Huang, XS | 1 |
| Guo, C | 1 |
| Morén, C | 1 |
| deSouza, RM | 1 |
| Giraldo, DM | 1 |
| Uff, C | 1 |
| Asemi-Rad, A | 1 |
| Moafi, M | 1 |
| Aliaghaei, A | 1 |
| Abbaszadeh, HA | 1 |
| Abdollahifar, MA | 1 |
| Ebrahimi, MJ | 1 |
| Heidari, MH | 1 |
| Sadeghi, Y | 1 |
| Verma, AK | 1 |
| Singh, S | 2 |
| Rizvi, SI | 1 |
| Wang, P | 1 |
| Zhang, S | 1 |
| Hu, C | 1 |
| Ren, L | 1 |
| Bi, J | 1 |
| Yoo, YM | 1 |
| Joo, SS | 1 |
| Tchekalarova, J | 1 |
| Tzoneva, R | 1 |
| Khezri, MR | 1 |
| Esmaeili, A | 1 |
| Ghasemnejad-Berenji, M | 1 |
| Al Kury, LT | 2 |
| Zeb, A | 1 |
| Abidin, ZU | 1 |
| Irshad, N | 1 |
| Malik, I | 1 |
| Alvi, AM | 1 |
| Khalil, AAK | 1 |
| Ahmad, S | 1 |
| Faheem, M | 1 |
| Khan, AU | 1 |
| Shah, FA | 2 |
| Li, S | 1 |
| Onaolapo, OJ | 1 |
| Onaolapo, AY | 1 |
| Olowe, OA | 1 |
| Udoh, MO | 1 |
| Udoh, DO | 1 |
| Nathaniel, TI | 1 |
| García, S | 1 |
| Martín Giménez, VM | 1 |
| Mocayar Marón, FJ | 1 |
| Manucha, W | 1 |
| Socaciu, AI | 1 |
| Ionuţ, R | 1 |
| Socaciu, MA | 1 |
| Ungur, AP | 1 |
| Bârsan, M | 1 |
| Chiorean, A | 1 |
| Socaciu, C | 1 |
| Râjnoveanu, AG | 1 |
| A Abdel Jaleel, G | 1 |
| A Al-Awdan, S | 1 |
| F Ahmed, R | 1 |
| A H Ahmed-Farid, O | 1 |
| Saleh, DO | 1 |
| Chen, D | 3 |
| Zhang, T | 2 |
| Lee, TH | 1 |
| Wu, J | 1 |
| Bai, Y | 1 |
| Wang, Y | 1 |
| Ma, J | 1 |
| Voysey, ZJ | 1 |
| Barker, RA | 1 |
| Lazar, AS | 1 |
| Melhuish Beaupre, LM | 1 |
| Brown, GM | 3 |
| Gonçalves, VF | 1 |
| Kennedy, JL | 1 |
| Novais, AA | 1 |
| Chuffa, LGA | 1 |
| Zuccari, DAPC | 1 |
| Alamdari, AF | 1 |
| Rahnemayan, S | 1 |
| Rajabi, H | 1 |
| Vahed, N | 1 |
| Kashani, HRK | 1 |
| Rezabakhsh, A | 1 |
| Sanaie, S | 1 |
| Zakria, M | 1 |
| Ahmad, N | 1 |
| Alattar, A | 1 |
| Uddin, Z | 1 |
| Siraj, S | 1 |
| Ullah, S | 1 |
| Alshaman, R | 1 |
| Khan, MI | 1 |
| Ramos, E | 1 |
| Egea, J | 3 |
| Marco-Contelles, J | 1 |
| Romero, A | 2 |
| Catalán, Ú | 1 |
| Barrubés, L | 1 |
| Valls, RM | 1 |
| Solà, R | 1 |
| Rubió, L | 1 |
| Wongprayoon, P | 1 |
| Vallée, A | 1 |
| Lecarpentier, Y | 1 |
| Guillevin, R | 1 |
| Vallée, JN | 1 |
| Esparza, JL | 1 |
| Gómez, M | 1 |
| Domingo, JL | 1 |
| Corpas, R | 1 |
| Griñán-Ferré, C | 1 |
| Palomera-Ávalos, V | 1 |
| Porquet, D | 1 |
| García de Frutos, P | 1 |
| Franciscato Cozzolino, SM | 1 |
| Rodríguez-Farré, E | 1 |
| Pallàs, M | 3 |
| Sanfeliu, C | 1 |
| Cardoso, BR | 1 |
| Muhammad, T | 1 |
| Ali, T | 2 |
| Ikram, M | 1 |
| Khan, A | 1 |
| Alam, SI | 1 |
| Kim, MO | 2 |
| Abbott, SM | 1 |
| Malkani, RG | 1 |
| Zee, PC | 1 |
| Yanar, K | 1 |
| Simsek, B | 1 |
| Çakatay, U | 1 |
| Shukla, M | 1 |
| Chinchalongporn, V | 1 |
| Song, J | 1 |
| Polimeni, G | 1 |
| Esposito, E | 1 |
| Bevelacqua, V | 1 |
| Guarneri, C | 1 |
| Cuzzocrea, S | 1 |
| Arushanian, ÉB | 2 |
| Allagui, MS | 1 |
| Feriani, A | 1 |
| Saoudi, M | 1 |
| Badraoui, R | 1 |
| Bouoni, Z | 1 |
| Nciri, R | 1 |
| Murat, JC | 1 |
| Elfeki, A | 1 |
| Anderson, G | 1 |
| Maes, M | 1 |
| Joshi, N | 1 |
| Biswas, J | 1 |
| Nath, C | 1 |
| Laudon, M | 1 |
| Frydman-Marom, A | 1 |
| Nguyen, XK | 1 |
| Lee, J | 1 |
| Shin, EJ | 1 |
| Dang, DK | 1 |
| Jeong, JH | 1 |
| Nguyen, TT | 1 |
| Nam, Y | 1 |
| Cho, HJ | 1 |
| Lee, JC | 1 |
| Park, DH | 1 |
| Jang, CG | 1 |
| Hong, JS | 1 |
| Nabeshima, T | 1 |
| Kim, HC | 1 |
| Paradies, G | 1 |
| Paradies, V | 1 |
| Ruggiero, FM | 1 |
| Petrosillo, G | 1 |
| Hardeland, R | 3 |
| Cardinali, DP | 3 |
| Pandi-Perumal, SR | 3 |
| Karaaslan, C | 1 |
| Suzen, S | 1 |
| Miller, E | 1 |
| Morel, A | 1 |
| Saso, L | 1 |
| Saluk, J | 1 |
| Colin-Gonzalez, AL | 1 |
| Aguilera, G | 1 |
| Serratos, IN | 1 |
| Escribano, BM | 1 |
| Santamaria, A | 1 |
| Tunez, I | 1 |
| Zhang, W | 1 |
| Chen, XY | 1 |
| Su, SW | 1 |
| Jia, QZ | 1 |
| Ding, T | 1 |
| Zhu, ZN | 1 |
| Rudnitskaya, EA | 1 |
| Muraleva, NA | 1 |
| Maksimova, KY | 1 |
| Kiseleva, E | 1 |
| Kolosova, NG | 1 |
| Stefanova, NA | 1 |
| Buendia, I | 1 |
| Navarro, E | 1 |
| Michalska, P | 1 |
| Gameiro, I | 1 |
| Abril, S | 1 |
| López, A | 1 |
| López, MG | 1 |
| León, R | 1 |
| Pacini, N | 1 |
| Borziani, F | 1 |
| Lim, Y | 1 |
| Cho, H | 1 |
| Kim, EK | 1 |
| Trotti, LM | 1 |
| Karroum, EG | 1 |
| Kuklina, EM | 1 |
| McCarter, SJ | 1 |
| Howell, MJ | 1 |
| Pillai, JA | 1 |
| Leverenz, JB | 1 |
| Paredes, SD | 1 |
| Korkmaz, A | 1 |
| Manchester, LC | 1 |
| Tan, DX | 2 |
| Kaur, C | 4 |
| Ling, EA | 1 |
| Wang, X | 2 |
| Figueroa, BE | 1 |
| Stavrovskaya, IG | 1 |
| Zhang, Y | 1 |
| Sirianni, AC | 1 |
| Zhu, S | 1 |
| Day, AL | 1 |
| Kristal, BS | 1 |
| Friedlander, RM | 1 |
| Guven, A | 1 |
| Yavuz, O | 1 |
| Cam, M | 1 |
| Comunoglu, C | 1 |
| Sevi'nc, O | 1 |
| Lauterbach, EC | 1 |
| Victoroff, J | 1 |
| Coburn, KL | 1 |
| Shillcutt, SD | 1 |
| Doonan, SM | 1 |
| Mendez, MF | 1 |
| Camins, A | 2 |
| Sureda, FX | 1 |
| Junyent, F | 1 |
| Verdaguer, E | 1 |
| Folch, J | 1 |
| Beas-Zarate, C | 1 |
| Gutierrez-Cuesta, J | 1 |
| Tajes, M | 1 |
| Jimenez, A | 1 |
| Escames, G | 2 |
| López, LC | 2 |
| García, JA | 1 |
| García-Corzo, L | 1 |
| Ortiz, F | 1 |
| Acuña-Castroviejo, D | 2 |
| Cecon, E | 1 |
| Markus, RP | 1 |
| BaHammam, AS | 1 |
| Spence, DW | 1 |
| Bharti, VK | 1 |
| Srinivasan, V | 2 |
| Mayo, JC | 1 |
| Sainz, RM | 1 |
| Lopez-Burillo, S | 1 |
| Ananth, C | 1 |
| Gopalakrishnakone, P | 1 |
| Lahiri, DK | 4 |
| Ge, YW | 1 |
| Bondy, SC | 3 |
| Sharman, EH | 3 |
| Magri, F | 1 |
| Sarra, S | 1 |
| Cinchetti, W | 1 |
| Guazzoni, V | 1 |
| Fioravanti, M | 1 |
| Cravello, L | 1 |
| Ferrari, E | 1 |
| Benitez-King, G | 2 |
| Ramírez-Rodríguez, G | 1 |
| Ortíz, L | 1 |
| Meza, I | 1 |
| Perreau, VM | 1 |
| Sharman, KZ | 1 |
| Campbell, A | 1 |
| Zhou, J | 1 |
| Lahiri, P | 2 |
| Rogers, JT | 1 |
| Greig, NH | 2 |
| Bondy, S | 2 |
| Olakowska, E | 1 |
| Marcol, W | 1 |
| Kotulska, K | 1 |
| Lewin-Kowalik, J | 1 |
| Maestroni, GJ | 1 |
| Esquifino, AI | 1 |
| Chen, DM | 1 |
| Claustrat, B | 1 |
| Rodriguez, MI | 1 |
| Herrera, F | 1 |
| Martin, V | 1 |
| García-Santos, G | 1 |
| Rodriguez-Blanco, J | 1 |
| Antolín, I | 1 |
| Rodriguez, C | 1 |
| Hoang, BX | 1 |
| Shaw, DG | 1 |
| Pham, PT | 1 |
| Levine, SA | 1 |
| Díaz López, B | 1 |
| Colmenero Urquijo, MD | 1 |
| Marín Fernández, B | 1 |
| Lin, AM | 1 |
| Ho, LT | 1 |
| Parmar, P | 1 |
| Daya, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Is Dietary Melatonin Supplementation a Viable Adjunctive Therapy for Chronic Periodontitis? A Preliminary Randomized Clinical Trial.[NCT03368430] | Phase 4 | 74 participants (Actual) | Interventional | 2016-07-04 | Completed | ||
| Open Label,Crossover,Pilot Study to Assess the Efficacy & Safety of Perispinal Admin.of Etanercept(Enbrel®) in Comb.w/Nutritional Supplements vs. Nutritional Supplements Alone in Subj. w/Mild to Mod. Alzheimer's Disease Receiving Std. Care.[NCT01716637] | Phase 1 | 12 participants (Anticipated) | Interventional | 2010-02-28 | Completed | ||
| A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia[NCT00505765] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Effect of Melatonin Administration on the PER1 and BMAL1 Clock Genes in Patients With Parkinson's Disease[NCT04287543] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2021-05-31 | Withdrawn (stopped due to Due to the COVID-19 pandemic, we were unable to begin the study) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 3.9 |
| AL-108, 5 mg/Day | 4.6 |
| Placebo | 3.2 |
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 1.3 |
| AL-108, 5 mg/Day | 2.3 |
| Placebo | -0.2 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | -0.4 |
| AL-108, 5 mg/Day | -1.2 |
| Placebo | -0.3 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 0.1 |
| AL-108, 5 mg/Day | -0.6 |
| Placebo | -0.1 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 4.9 |
| AL-108, 5 mg/Day | 8.9 |
| Placebo | 0.3 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 2.9 |
| AL-108, 5 mg/Day | 7.2 |
| Placebo | -0.9 |
72 reviews available for melatonin and Neurodegenerative Diseases
| Article | Year |
|---|---|
Potentiating the Benefits of Melatonin through Chemical Functionalization: Possible Impact on Multifactorial Neurodegenerative Disorders.
Topics: Animals; Antioxidants; Humans; Melatonin; Neurodegenerative Diseases | 2021 |
Melatonin hormone as a therapeutic weapon against neurodegenerative diseases.
Topics: Alzheimer Disease; Animals; Antioxidants; Humans; Melatonin; Neurodegenerative Diseases; Neuroprotec | 2021 |
The Involvement of Melatonin and Tasimelteon against Alzheimer's Disease.
Topics: Alzheimer Disease; Humans; Melatonin; Neurodegenerative Diseases; Sleep Initiation and Maintenance D | 2023 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti- | 2022 |
Antioxidant Therapeutic Strategies in Neurodegenerative Diseases.
Topics: Antioxidants; Humans; Melatonin; Mitochondria; Neurodegenerative Diseases; Oxidative Stress | 2022 |
Therapeutic potential of melatonin and its derivatives in aging and neurodegenerative diseases.
Topics: Aging; Animals; Antioxidants; Humans; Mammals; Melatonin; Mitochondria; Neurodegenerative Diseases | 2023 |
Melatonin Can Modulate Neurodegenerative Diseases by Regulating Endoplasmic Reticulum Stress.
Topics: Aged; Alzheimer Disease; Antioxidants; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum St | 2023 |
Oxidative Stress and Aging as Risk Factors for Alzheimer's Disease and Parkinson's Disease: The Role of the Antioxidant Melatonin.
Topics: Aged; Aging; Alzheimer Disease; Antioxidants; Humans; Melatonin; Neurodegenerative Diseases; Oxidati | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Role of Bmal1 and Gut Microbiota in Alzheimer's Disease and Parkinson's Disease Pathophysiology: The Probable Effect of Melatonin on Their Association.
Topics: Alzheimer Disease; Gastrointestinal Microbiome; Humans; Melatonin; Neurodegenerative Diseases; Parki | 2023 |
Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders.
Topics: Animals; Antioxidants; Brain; Gene Expression; Humans; Melatonin; Mitochondria; Neurodegenerative Di | 2020 |
Melatonin and cannabinoids: mitochondrial-targeted molecules that may reduce inflammaging in neurodegenerative diseases.
Topics: Animals; Cannabinoids; Humans; Inflammation; Melatonin; Mitochondria; Neurodegenerative Diseases | 2020 |
Melatonin, an ubiquitous metabolic regulator: functions, mechanisms and effects on circadian disruption and degenerative diseases.
Topics: Aging; Animals; Chronobiology Disorders; Humans; Melatonin; Metabolic Networks and Pathways; Metabol | 2020 |
Cellular Mechanisms of Melatonin: Insight from Neurodegenerative Diseases.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Circadian Rhythm; Dementia, Vascular; Hum | 2020 |
Melatonin and regulation of autophagy: Mechanisms and therapeutic implications.
Topics: Animals; Autophagy; Cell Death; Humans; Melatonin; Neoplasms; Neurodegenerative Diseases; Reperfusio | 2021 |
The Treatment of Sleep Dysfunction in Neurodegenerative Disorders.
Topics: Behavior Therapy; Humans; Melatonin; Neurodegenerative Diseases; Quality of Life; Sleep; Sleep Wake | 2021 |
Melatonin's neuroprotective role in mitochondria and its potential as a biomarker in aging, cognition and psychiatric disorders.
Topics: Aging; Animals; Antioxidants; Biomarkers; Cognition; Humans; Melatonin; Mental Disorders; Mitochondr | 2021 |
Exosomes and Melatonin: Where Their Destinies Intersect.
Topics: Animals; Brain Diseases; Colitis; Exosomes; Humans; Kidney Diseases; Liver Diseases; Melatonin; Neop | 2021 |
Melatonin as a promising modulator of aging related neurodegenerative disorders: Role of microRNAs.
Topics: Aging; Animals; Brain; Humans; Melatonin; MicroRNAs; Neurodegenerative Diseases; Neuroprotective Age | 2021 |
Melatonin as a versatile molecule to design novel multitarget hybrids against neurodegeneration.
Topics: Drug Design; Humans; Melatonin; Molecular Structure; Neurodegenerative Diseases; Neuroprotective Age | 2017 |
In vitro Metabolomic Approaches to Investigating the Potential Biological Effects of Phenolic Compounds: An Update.
Topics: Catecholamines; Diabetes Mellitus, Type 2; Humans; Melatonin; Metabolomics; Neurodegenerative Diseas | 2017 |
Melatonin as a mitochondrial protector in neurodegenerative diseases.
Topics: Animals; Antioxidants; Humans; Melatonin; Mitochondria; Mitochondrial Diseases; Neurodegenerative Di | 2017 |
Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms.
Topics: Adenosine Triphosphate; Aerobiosis; Amyotrophic Lateral Sclerosis; Brain; Circadian Rhythm; Energy M | 2018 |
Role of Melatonin in Aluminum-Related Neurodegenerative Disorders: a Review.
Topics: Aluminum; Animals; Antioxidants; Humans; Melatonin; Neurodegenerative Diseases; Neurotoxicity Syndro | 2019 |
Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases.
Topics: Animals; Humans; Melatonin; Neurodegenerative Diseases; Phosphoprotein Phosphatases | 2018 |
Circadian disruption and human health: A bidirectional relationship.
Topics: Circadian Rhythm; Humans; Melatonin; Neurodegenerative Diseases | 2020 |
Integration of Melatonin Related Redox Homeostasis, Aging, and Circadian Rhythm.
Topics: Aging; Animals; Caloric Restriction; Chronotherapy; Circadian Rhythm; Circadian Rhythm Signaling Pep | 2019 |
The role of melatonin in targeting cell signaling pathways in neurodegeneration.
Topics: Animals; Apoptosis; Calcium; Homeostasis; Humans; Insulin; Melatonin; Mitochondria; Neurodegenerativ | 2019 |
Pineal gland dysfunction in Alzheimer's disease: relationship with the immune-pineal axis, sleep disturbance, and neurogenesis.
Topics: Alzheimer Disease; Animals; Circadian Rhythm; Humans; Melatonin; Neurodegenerative Diseases; Neuroge | 2019 |
Role of melatonin supplementation in neurodegenerative disorders.
Topics: Dietary Supplements; Humans; Melatonin; Neurodegenerative Diseases | 2014 |
[Melatonin as a drug: present-day status and prospects].
Topics: Animals; Antioxidants; Circadian Rhythm; Drug Administration Schedule; Drug Synergism; Humans; Melat | 2013 |
Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders.
Topics: Humans; Inflammation; Melatonin; Mental Disorders; Neurodegenerative Diseases; Serotonin | 2014 |
[Melatonin as a drug: present status and perspectives].
Topics: Anti-Anxiety Agents; Antioxidants; Central Nervous System; Circadian Rhythm; Depression; Drug Admini | 2014 |
Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.
Topics: Animals; Antioxidants; Apoptosis; Humans; Melatonin; Models, Biological; Neurodegenerative Diseases; | 2015 |
Therapeutic effects of melatonin receptor agonists on sleep and comorbid disorders.
Topics: Acetamides; Animals; Benzofurans; Clinical Trials as Topic; Cyclopropanes; Humans; Hypnotics and Sed | 2014 |
Protective role of melatonin in mitochondrial dysfunction and related disorders.
Topics: Animals; Antioxidants; Cardiolipins; Cardiovascular Diseases; Diabetes Mellitus; Humans; Melatonin; | 2015 |
Melatonin and brain inflammaging.
Topics: Aging; Animals; Brain; Humans; Immunosenescence; Melatonin; Neurodegenerative Diseases; Neuroimmunom | 2015 |
Antioxidant properties of melatonin and its potential action in diseases.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Clinical Trials as Topic; Diabetes Mellitus; Humans | 2015 |
Melatonin redox activity. Its potential clinical applications in neurodegenerative disorders.
Topics: Animals; Humans; Melatonin; Neurodegenerative Diseases; Oxidation-Reduction | 2015 |
On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress.
Topics: Animals; Antioxidants; Biological Clocks; Circadian Rhythm; Humans; Melatonin; Mental Disorders; Neu | 2015 |
Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials.
Topics: Humans; Hypnotics and Sedatives; Melatonin; Neurodegenerative Diseases; Randomized Controlled Trials | 2016 |
Oncostatic-Cytoprotective Effect of Melatonin and Other Bioactive Molecules: A Common Target in Mitochondrial Respiration.
Topics: Animals; Cell Respiration; Cytostatic Agents; Humans; Melatonin; Metabolome; Mitochondria; Mitochond | 2016 |
Brain metabolism as a modulator of autophagy in neurodegeneration.
Topics: Alzheimer Disease; Animals; Autophagy; Brain; Cholesterol; Ghrelin; Glucose; Glycogen; Homeostasis; | 2016 |
Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases.
Topics: Central Nervous System Depressants; Humans; Melatonin; Neurodegenerative Diseases; Sleep Wake Disord | 2016 |
[Melatonin as an inducing factor for multiple sclerosis].
Topics: Humans; Immunomodulation; Interleukin-17; Melatonin; Multiple Sclerosis; Neurodegenerative Diseases; | 2016 |
Importance of Rapid Eye Movement Sleep Behavior Disorder to the Primary Care Physician.
Topics: Central Nervous System Depressants; Clonazepam; Diagnosis, Differential; GABA Modulators; Humans; Me | 2016 |
Sleep and Neurodegeneration: A Critical Appraisal.
Topics: Alzheimer Disease; Dementia; Humans; Lewy Body Disease; Melatonin; Multiple System Atrophy; Neurodeg | 2017 |
Melatonin in relation to the "strong" and "weak" versions of the free radical theory of aging.
Topics: Aging; Animals; Free Radicals; Humans; Melatonin; Neurodegenerative Diseases | 2008 |
Antioxidants and neuroprotection in the adult and developing central nervous system.
Topics: Animals; Antioxidants; Antipyrine; Apoptosis; Central Nervous System; Edaravone; Free Radical Scaven | 2008 |
The antiapoptotic activity of melatonin in neurodegenerative diseases.
Topics: Animals; Apoptosis; Humans; Melatonin; Models, Biological; Neurodegenerative Diseases; Neuroprotecti | 2009 |
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipsychotic Agents; Benzodiazepines; Benzo | 2010 |
An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders.
Topics: Animals; Apoptosis; Drug Design; Drugs, Investigational; Humans; Melatonin; Mitochondria; Neurodegen | 2010 |
[Effects of melatonin in the brain of the senescence-accelerated mice-prone 8 (SAMP8) model].
Topics: Aging; Animals; Antioxidants; Biomarkers; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycog | 2011 |
Mitochondrial DNA and inflammatory diseases.
Topics: Autoimmune Diseases; Carrier Proteins; DNA, Mitochondrial; Humans; Immunity, Innate; Inflammation; M | 2012 |
Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders.
Topics: Alzheimer Disease; Antioxidants; Encephalitis; Humans; Melatonin; Neurodegenerative Diseases; Pineal | 2011 |
Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.
Topics: Aging; Animals; Antioxidants; Apoptosis; Brain Injuries; Circadian Rhythm; Clinical Trials as Topic; | 2013 |
Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerative diseases.
Topics: Animals; DNA Damage; Humans; Light; Melatonin; Neoplasms; Neurodegenerative Diseases | 2002 |
Melatonin oxidative stress and neurodegenerative diseases.
Topics: Animals; Antioxidants; Disease Models, Animal; Free Radical Scavengers; Humans; Melatonin; Neurodege | 2002 |
Melatonin, longevity and health in the aged: an assessment.
Topics: Age Factors; Aging; Animals; Female; Free Radicals; Melatonin; Mice; Neurodegenerative Diseases; Oxi | 2002 |
The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia.
Topics: Animals; Brain; Cytoskeleton; Humans; Lewy Bodies; Melatonin; Microtubule-Associated Proteins; Neuro | 2004 |
Retardation of brain aging by chronic treatment with melatonin.
Topics: Aging; Animals; Brain; Cytokines; Gene Expression Regulation; Humans; Inflammation; Melatonin; Neuro | 2004 |
Melatonin, metals, and gene expression: implications in aging and neurodegenerative disorders.
Topics: Aging; Animals; Dietary Supplements; Drug Interactions; Gene Expression; Humans; Melatonin; Metals; | 2004 |
The role of melatonin in the neurodegenerative diseases.
Topics: Animals; Free Radicals; Humans; Melatonin; Nervous System; Nervous System Physiological Phenomena; N | 2005 |
Role of melatonin in neurodegenerative diseases.
Topics: Aging; Alzheimer Disease; Animals; Antioxidants; Brain Chemistry; Brain Injuries; Free Radical Scave | 2005 |
Melatonin as a cytoskeletal modulator: implications for cell physiology and disease.
Topics: Actin Cytoskeleton; Animals; Calmodulin; Cell Line; Cytoskeleton; Free Radicals; Humans; Melatonin; | 2006 |
Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases.
Topics: Aging; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Cell Physiological Phenomena; Cho | 2005 |
[Disruptions of circadian rhythm in neurologic disorders].
Topics: Autonomic Nervous System Diseases; Body Temperature Regulation; Brain Neoplasms; Central Nervous Sys | 2006 |
Melatonin role in the mitochondrial function.
Topics: Animals; Humans; Inflammation; Melatonin; Mitochondria; Mitochondrial Diseases; Neurodegenerative Di | 2007 |
Melatonin and the aging brain.
Topics: Aging; Animals; Brain; Brain Chemistry; Encephalitis; Gene Expression Regulation, Enzymologic; Human | 2007 |
Neurobiological effects of melatonin as related to cancer.
Topics: Aging; Antineoplastic Agents; Biological Clocks; Clinical Trials as Topic; Drug Evaluation, Preclini | 2007 |
[The antioxidant capacity of melatonin: its defensive role against age-related diseases].
Topics: Age Factors; Aged; Aging; Animals; Antioxidants; Female; Free Radicals; Humans; Life Expectancy; Mal | 1998 |
Oxidative damage in the central nervous system: protection by melatonin.
Topics: Animals; Antioxidants; Central Nervous System Diseases; Disease Models, Animal; Free Radical Scaveng | 1998 |
1 trial available for melatonin and Neurodegenerative Diseases
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
26 other studies available for melatonin and Neurodegenerative Diseases
| Article | Year |
|---|---|
Gramine Derivatives Targeting Ca(2+) Channels and Ser/Thr Phosphatases: A New Dual Strategy for the Treatment of Neurodegenerative Diseases.
Topics: Alkaloids; Animals; Calcium Channels; Cattle; Cell Survival; Dose-Response Relationship, Drug; Hippo | 2016 |
Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biphenyl Compounds; Cell Line; Cell Survival; Cycl | 2020 |
Melatonin Induces Autophagy in Amyotrophic Lateral Sclerosis Mice via Upregulation of SIRT1.
Topics: Amyotrophic Lateral Sclerosis; Animals; Autophagy; Beclin-1; Melatonin; Mice; Neurodegenerative Dise | 2022 |
Melatonin Attenuates Methamphetamine-Induced Alteration of Amyloid β Precursor Protein Cleaving Enzyme Expressions via Melatonin Receptor in Human Neuroblastoma Cells.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Pr | 2022 |
Novel melatonin-trientine conjugate as potential therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Chelating A | 2022 |
The effect of dopaminergic neuron transplantation and melatonin co-administration on oxidative stress-induced cell death in Parkinson's disease.
Topics: Animals; Cell Death; Dopaminergic Neurons; Glutathione; Melatonin; Neurodegenerative Diseases; Oxida | 2022 |
Regulatory role of melatonin in Notch1 signaling pathway in cerebral cortex of Aβ
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Melatonin; Neurodegenerative Diseases; Peptide Fragment | 2023 |
Neuroprotective effects of melatonin and celecoxib against ethanol-induced neurodegeneration: a computational and pharmacological approach.
Topics: Animals; Celecoxib; Computational Biology; Disease Models, Animal; Ethanol; Injections, Intraperiton | 2019 |
Melatonin regulates neurodegenerative complications associated with NAFLD via enhanced neurotransmission and cellular integrity: a correlational study.
Topics: Animals; Antioxidants; Brain; Cellular Microenvironment; Diet, High-Fat; Liver; Male; Melatonin; Neu | 2020 |
Melatonin rescues the mice brain against cisplatin-induced neurodegeneration, an insight into antioxidant and anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Blotting, Western; Brain; Cisplatin; Fluorescent An | 2021 |
Melatonin induces mechanisms of brain resilience against neurodegeneration.
Topics: Animals; Blotting, Western; Brain; Cognition; Dementia; Intercellular Signaling Peptides and Protein | 2018 |
Melatonin Rescue Oxidative Stress-Mediated Neuroinflammation/ Neurodegeneration and Memory Impairment in Scopolamine-Induced Amnesia Mice Model.
Topics: Amnesia; Animals; Antioxidants; Apoptosis; Brain-Derived Neurotrophic Factor; Cyclic AMP Response El | 2019 |
Effects of melatonin on aluminium-induced neurobehavioral and neurochemical changes in aging rats.
Topics: Acetylcholinesterase; Aging; Aluminum; Animals; Behavior, Animal; Body Weight; Brain; Catalase; Glut | 2014 |
Liposomal melatonin rescues methamphetamine-elicited mitochondrial burdens, pro-apoptosis, and dopaminergic degeneration through the inhibition PKCδ gene.
Topics: Animals; Antioxidants; Apoptosis; Dopamine; Dopamine Uptake Inhibitors; Liposomes; Melatonin; Metham | 2015 |
Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3β pathway in the mouse hippocampus.
Topics: Amyloid beta-Peptides; Animals; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hippoca | 2015 |
Melatonin Attenuates Memory Impairment, Amyloid-β Accumulation, and Neurodegeneration in a Rat Model of Sporadic Alzheimer's Disease.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim | 2015 |
New melatonin-cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection.
Topics: Animals; Antioxidants; Cinnamates; Humans; Melatonin; Molecular Structure; Neurodegenerative Disease | 2015 |
Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury.
Topics: Animals; Antioxidants; Blotting, Western; Brain Ischemia; Carbonic Anhydrase Inhibitors; Caspase 1; | 2009 |
Central nervous system complications of diabetes in streptozotocin-induced diabetic rats: a histopathological and immunohistochemical examination.
Topics: Animals; Antioxidants; Brain Chemistry; Central Nervous System Diseases; Cerebellum; Cerebral Cortex | 2009 |
The pineal hormone melatonin in health and disease.
Topics: Humans; Melatonin; Neoplasms; Neurodegenerative Diseases; Pineal Gland; Sleep Wake Disorders | 2011 |
Protective role of melatonin in domoic acid-induced neuronal damage in the hippocampus of adult rats.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Astrocytes; Avian Proteins; Basigin; B | 2003 |
Dietary supplementation with melatonin reduces levels of amyloid beta-peptides in the murine cerebral cortex.
Topics: Aging; Amyloid beta-Peptides; Animals; Antioxidants; Blotting, Western; Cerebral Cortex; Dietary Sup | 2004 |
Qualitative and quantitative changes of melatonin levels in physiological and pathological aging and in centenarians.
Topics: Adult; Aged; Aged, 80 and over; Aging; Circadian Rhythm; Female; Humans; Male; Melatonin; Neurodegen | 2004 |
Melatonin prevents glutamate-induced oxytosis in the HT22 mouse hippocampal cell line through an antioxidant effect specifically targeting mitochondria.
Topics: Animals; Antioxidants; Cell Death; Cell Line; Dose-Response Relationship, Drug; Excitatory Amino Aci | 2007 |
Melatonin suppresses iron-induced neurodegeneration in rat brain.
Topics: Animals; Antioxidants; Brain; Chromans; Dopamine; Glutathione; Immunohistochemistry; Infusion Pumps, | 2000 |
The effect of copper on (3H)-tryptophan metabolism in organ cultures of rat pineal glands.
Topics: Animals; Copper; Free Radicals; Indoles; Male; Melatonin; Neurodegenerative Diseases; Organ Culture | 2001 |